Cardiovascular-Kidney Metabolic Syndrome

Cardiovascular–Kidney–Metabolic (CKM) syndrome describes an integrated pathophysiological continuum characterized by the coexistence of metabolic dysfunction, renal impairment, and cardiovascular disease. Recognizing CKM syndrome at an early stage is vital, as the combined effects of these interrelated disorders significantly worsen patient outcomes. We aim to summarize the latest evidence regarding CKM syndrome and to highlight emerging therapeutic strategies that support comprehensive risk reduction for affected individuals. This is a review, drawing upon recent clinical trials, updated guidelines, and epidemiological data. The development and progression of CKM syndrome are driven by intersecting mechanisms, including overactivation of the renin-angiotensin-aldosterone system (RAAS), chronic inflammation, oxidative stress, and metabolic dysregulation. Patients who present early metabolic abnormalities are at a heightened risk for rapid deterioration of renal function and increased rates of cardiovascular events. Integrated management approaches that emphasize early screening, lifestyle modification, optimization of glycemic control and blood pressure, alongside RAAS-targeted therapies, have shown to improve clinical outcomes in these patients. CKM syndrome necessitates a unified, multisystem approach for both prevention and treatment. Early identification of at-risk individuals and the timely incorporation of appropriate therapeutic interventions can significantly reduce the incidence of renal and cardiovascular complications. It is essential to strengthen multidisciplinary care pathways to effectively mitigate the long-term burden associated with this syndrome.